Opinion
Video
Carol Ann Huff, MD discusses how the approval of additional bispecific antibodies for multiple myeloma might change the treatment selection process, highlighting considerations for sequencing of agents and combination therapy.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
2 Commerce Drive
Cranbury, NJ 08512